cavity has about a total volume of 15–20 ml with a total surface area of 150 cm2;
therefore, volume that can be delivered into the nasal cavity is restricted to
25–200 µl. The total volume of developed potassium channel opener
nanosuspension administered to the nasal cavity of the animals was 0.1 ml
(100µl), which showed a safe delivery system since; no toxicity in nasal mucosa
and brain was observed, with the treated animals. Thus nanosuspension is a good
approach to deliver drugs to brain via nasal route of administration.
current study, we described the development of ezogabine nanosuspension by
means of nanoprecipitation-ultrasonication method. The main objective of this
study was to enhance the aqueous solubility and to develop brain targeted drug
delivery of ezogabine by 32 factorial design. The plain suspension
was prepared for comparison with nanosuspension. The factorial design showed
promising approach to study the effect of polymer conc. (X1) and
ultrasonication time (X2) on particle size (Y1),
saturation solubility (Y2) and in-vitro drug diffusion (Y3).
The formulation showed better results in terms of drug content, zeta potential,
SEM, TEM and stability study. The formulation showed better antiepileptic
activity when checked against maximal electro-shock-induced convulsions in
rats. This preparation was capable to show higher drug concentration in brain
and no mortality when formulation was administered intranasally. Thus it was
concluded that ezogabine nanosuspension was capable of providing direct
nose-to-brain delivery, thereby enhancing drug concentration in the brain.
The authors thanks to the Management
and Principal of MES’s College of Pharmacy, Sonai for providing good laboratory
facilities, Dr. Rajurkar, Dr. Khanage, Dr. Mohite, Dr. Pandhare, Mr. Aher for
their support and encouragement. The authors also thanks to Lupin
pharma, Aurangabad, for providing gift sample of Ezogabine, Cochin University,
Kerala, for recording of SEM and TEM.
White H S.
Preclinical Development of Antiepileptic Drugs: Past, Present, and Future Directions.Epilepsia.
(2003) 44(7): 2–8.
Lopez M, Osornio M and Marquez S. In Vivo Experimental Models of
Epilepsy.Bentham Science Publishers Ltd. (2010) 10:298-309.
M, Kannan K, Manavalan R and Senthamarai.Formulation and in vivo Evaluation
of Niosomes containing Oxcarbazepine.J. Pharm. Sci. & Res. Vol.
(2013) 5(1): 8–11.
G, Aucharmal A L and Dethe S. Development of Ezogabine Co Crystal Formation: An
Efficient Approach to Enhance Aqueous Solubility.British Biomedical Bulletin.(2015)
Kinjal B, Patel A, Talele A and
Jadhav A G. An overview of Intranasal Nanosuspension for Brain
Targeted Drug Delivery, Indo American Journal of Pharmaceutical Research.(2015)
Shadab M, Mushir A, Rashid A, Aseem B, Sanjula B and Javed A. Donepezil
Nanosuspension Intended for Nose to Brain Targeting: In Vitro and In
Vivo Safety Evaluation.International Journal of Biological
Macromolecules.(2014) 67: 418-425.
Process for the Preparation of Dispersible Colloidal Systems of a Substance in
the Form of Nanoparticles. 1988, US Patent US5118528, 2.
D. Preparation Techniques and Mechanisms of Formation of Biodegradable
Nanoparticles from Preformed Polymers. Drug Dev. Ind. Pharm.(1998) 24:
Thakkar H P, Patel
B V and Thakkar
S P. Development and characterization of nanosuspensions of olmesartan
medoxomil for bioavailability enhancement.J Pharm
Bioallied Sci.(2011) 3(3): 426–434.
Sahu B P,
Das M K. Optimization of felodipine nanosuspensions using Full Factorial
Design, International Journal of PharmTech Research. (2013) 5(2):
Mittal A, Sharma K and Alam S.
Fabrication of Acetazolamide Loaded Nasal Nanosuspension: An In Vitro
and Ex Vivo Characterization.Analele Universitatii Dunarea De Jos
Agarwal V and
Bajpal M. Preparation and Optimization of Esomeprazole Nanosuspension using
Evaporative Precipitation–Ultrasonication.Tropical Journal of Pharmaceutical
Research.(2014) 13 (4): 497-503.
Peng Q, Hongze P, Hongyu P, Shaoping S, Yongmei Y and Fude C. Preparation of stable Nitrendipine
nanosuspensions using the precipitation–ultrasonication method for enhancement
of dissolution and oral bioavailability.European Journal of Pharmaceutical
Sciences.(2010) 40: 325–334.
14. Summary of Product Characteristics, http://www.ema.europa.eu/.
15. Sandhya J, Pavani A and Reddy R.
Formulation and evaluation of nanosuspension of Nisoldipine.International
Journal of Pharmaceutical Sciences Review and Research.(2014) 24(1):
16. Pandya V M,
Patel J K and Patel D J. Formulation,
Optimization and characterization of Simvastatin Nanosuspension prepared by
nanoprecipitation technique.Scholars Research Library Der Pharmacia Lettre.(2011) 3(2): 129-140.
17. R. M. Mehta,
Pharmaceutics II, Vallabh Prakashan 3rd edition, 132-133.
18. Nagajyothi N, Dhanalakshmi M, Thenmozhi S, Natarajan R and
Rajendran N. Formulation and evaluation of Pitavastatin nanosuspension.International
Journal of Pharmacy & Life Sciences.(2014) 5(2): 3318-3324.
19. Patel RB, Patel M R, Bhatt K K and Patel B G. Formulation
consideration and characterization of microemulsion drug delivery system for
transnasal administration of carbamazepine.Bulletin of Faculty of Pharmacy,
Cairo University.(2013) 51: 243–253.
20. Ullah S S.
Formulation and evaluation of directly compressed Ofloxacin Ethocel controlled
release Tablets: A Kinetic Approach.International Journal of Research in
Ayurveda and Pharmacy.(2015) 2(3): 801-809.
21. Snehamayee M. Application of Central Composite Design For
Optimization of Effervescent Floating Tablets using Hydrophilic Polymers.Asian
Journal of Pharmaceutical and Clinical Research.(2015) 8(1): 293-298.
22. Attari Z, Bhandari A and Jagdish P C. Enhanced ex-vivo
intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by
combinative technology.Saudi Pharmaceutical Journal.(2015) 03: 1-7.
23. Pardeikea J, Strohmeir D M, Schrodi N, Voura C andZimmer A.
Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble
drugs in personalized medicines,International Journal of Pharmaceutics.(2011).
24. Sahu B P and Das M K. Nanosuspension for enhancement of oral
bioavailability of felodipine.Appl Nanosci. (2014) 4: 189–197.
25. Venkatesh D N, Baskaran M, Karri V, Mannemala S,
Radhakrishna K and Goti S. Fabrication and in vivo evaluation of Nelfinavir loaded
PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect.Saudi
Pharmaceutical Journal.(2015), 23: 667–67.
H P, Patel B V and Thakkar S P. Development and characterization of nanosuspensions of
olmesartan medoxomil for bioavailability enhancement.J
Pharm Bioallied Sci.(2011) 3(3): 426–434.
Sheetal P. Preparation and evaluation of transnasal
microemulsion of carbamazepine.Asian Journal of Pharmaceutical Sciences.(2013)